Raymond James upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX – Free Report) to a strong-buy rating in a research report report published on Wednesday morning, Zacks.com reports.
Eupraxia Pharmaceuticals Stock Performance
EPRX stock opened at $2.85 on Wednesday. Eupraxia Pharmaceuticals has a 52 week low of $2.48 and a 52 week high of $6.78.
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.
Further Reading
- Five stocks we like better than Eupraxia Pharmaceuticals
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- EV Stocks and How to Profit from Them
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- Do ETFs Pay Dividends? What You Need to Know
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
